{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T02:51:18Z","timestamp":1781837478095,"version":"3.54.5"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41401-026-01767-z","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T08:23:56Z","timestamp":1772612636000},"page":"1955-1964","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted tumor starvation strategy augments radiosensitivity and enhances radioactive iodine-mediated tumor immunotherapy"],"prefix":"10.1038","volume":"47","author":[{"given":"Ying","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren-li","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-mei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-zheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Joon","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeongjin","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"1767_CR1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/pro6.1239","volume":"8","author":"TP Varghese","year":"2024","unstructured":"Varghese TP, John A, Mathew J. Revolutionizing cancer treatment: the role of radiopharmaceuticals in modern cancer therapy. Precis Radiat Oncol. 2024;8:145\u201352.","journal-title":"Precis Radiat Oncol"},{"key":"1767_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2023.215430","volume":"497","author":"J Guo","year":"2023","unstructured":"Guo J, Xiong H, Liu H, Zhang T, Sun X. Radioiodine based biomedical carriers for cancer theranostics. Coord Chem Rev. 2023;497:215430.","journal-title":"Coord Chem Rev"},{"key":"1767_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1146\/annurev-physiol-022516-034125","volume":"79","author":"S Ravera","year":"2017","unstructured":"Ravera S, Reyna-Neyra A, Ferrandino G, Amzel LM, Carrasco N. The sodium\/iodide symporter (NIS): molecular physiology and preclinical and clinical applications. Annu Rev Physiol. 2017;79:261\u201389.","journal-title":"Annu Rev Physiol"},{"key":"1767_CR4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/jlcr.3891","volume":"64","author":"T Ferris","year":"2021","unstructured":"Ferris T, Carroll L, Jenner S, Aboagye EO. Use of radioiodine in nuclear medicine\u2014a brief overview. J Label Comp Radiopharm. 2021;64:92\u2013108.","journal-title":"J Label Comp Radiopharm"},{"key":"1767_CR5","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.3390\/cancers14153800","volume":"14","author":"C Sparano","year":"2022","unstructured":"Sparano C, Moog S, Hadoux J, Dupuy C, Al Ghuzlan A, Breuskin I, et al. Strategies for radioiodine treatment: what\u2019s new. Cancers. 2022;14:3800.","journal-title":"Cancers"},{"key":"1767_CR6","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3390\/cancers13051102","volume":"13","author":"AE Kabakov","year":"2021","unstructured":"Kabakov AE, Yakimova AO. Hypoxia-induced cancer cell responses driving radioresistance of hypoxic tumors: approaches to targeting and radiosensitizing. Cancers. 2021;13:1102.","journal-title":"Cancers"},{"key":"1767_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.718636","volume":"11","author":"A Carlos-Reyes","year":"2021","unstructured":"Carlos-Reyes A, Mu\u00f1iz-Lino MA, Romero-Garcia S, L\u00f3pez-Camarillo C, Hern\u00e1ndez-de la Cruz ON. Biological adaptations of tumor cells to radiation therapy. Front Oncol. 2021;11:718636.","journal-title":"Front Oncol"},{"key":"1767_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw5473","volume":"368","author":"B Faubert","year":"2020","unstructured":"Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368:eaaw5473.","journal-title":"Science"},{"key":"1767_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/metabo11010028","volume":"11","author":"K Ohshima","year":"2021","unstructured":"Ohshima K, Morii E. Metabolic reprogramming of cancer cells during tumor progression and metastasis. Metabolites. 2021;11:28.","journal-title":"Metabolites"},{"key":"1767_CR10","doi-asserted-by":"crossref","unstructured":"Li AM, Ye J. Deciphering the Warburg effect: metabolic reprogramming, epigenetic remodeling, and cell dedifferentiation. Annu Rev Cancer Biol. 2024;8:35\u201358.","DOI":"10.1146\/annurev-cancerbio-062822-120857"},{"key":"1767_CR11","doi-asserted-by":"publisher","first-page":"811","DOI":"10.7150\/ijbs.79928","volume":"19","author":"Y Yu","year":"2023","unstructured":"Yu Y, Yu J, Ge S, Su Y, Fan X. Novel insight into metabolic reprogrammming in cancer radioresistance: a promising therapeutic target in radiotherapy. Int J Biol Sci. 2023;19:811.","journal-title":"Int J Biol Sci"},{"key":"1767_CR12","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1093\/advances\/nmaa174","volume":"12","author":"P Icard","year":"2021","unstructured":"Icard P, Loi M, Wu Z, Ginguay A, Lincet H, Robin E, et al. Metabolic strategies for inhibiting cancer development. Adv Nutr. 2021;12:1461\u201380.","journal-title":"Adv Nutr"},{"key":"1767_CR13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.tem.2021.03.003","volume":"32","author":"M Butler","year":"2021","unstructured":"Butler M, van der Meer LT, van Leeuwen FN. Amino acid depletion therapies: starving cancer cells to death. Trends Endocrinol Metab. 2021;32:367\u201381.","journal-title":"Trends Endocrinol Metab"},{"key":"1767_CR14","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1038\/s41416-022-01965-6","volume":"127","author":"M Falcone","year":"2022","unstructured":"Falcone M, Uribe AH, Papalazarou V, Newman AC, Athineos D, Stevenson K, et al. Sensitisation of cancer cells to radiotherapy by serine and glycine starvation. Br J Cancer. 2022;127:1773\u201386.","journal-title":"Br J Cancer"},{"key":"1767_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/07388550601173926","volume":"27","author":"N Verma","year":"2007","unstructured":"Verma N, Kuldeep K, Gurnoor K, Anand S. L-Asparaginase: a promising chemotherapeutic agent. Crit Rev Biotechnol. 2007;27:45\u201362.","journal-title":"Crit Rev Biotechnol"},{"key":"1767_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn6491","volume":"8","author":"M Grima-Reyes","year":"2022","unstructured":"Grima-Reyes M, Vandenberghe A, Nemazanyy I, Meola P, Paul R, Reverso-Meinietti J, et al. Tumoral microenvironment prevents de novo asparagine biosynthesis in B cell lymphoma, regardless of ASNS expression. Sci Adv. 2022;8:eabn6491.","journal-title":"Sci Adv"},{"key":"1767_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122740","volume":"312","author":"S Zhang","year":"2025","unstructured":"Zhang S, Gong L, Sun Y, Zhang F, Gao W. An ultra-long-acting L-asparaginase synergizes with an immune checkpoint inhibitor in starvation-immunotherapy of metastatic solid tumors. Biomaterials. 2025;312:122740.","journal-title":"Biomaterials"},{"key":"1767_CR18","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1042\/BJ20081847","volume":"417","author":"M Michalak","year":"2009","unstructured":"Michalak M, Groenendyk J, Szabo E, Gold LI, Opas M. Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem J. 2009;417:651\u201366.","journal-title":"Biochem J"},{"key":"1767_CR19","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","volume":"16","author":"AB Sharabi","year":"2015","unstructured":"Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015;16:e498\u2013e509.","journal-title":"Lancet Oncol"},{"key":"1767_CR20","doi-asserted-by":"publisher","first-page":"956","DOI":"10.2967\/jnumed.120.245290","volume":"62","author":"D-Y Kim","year":"2021","unstructured":"Kim D-Y, Pyo A, Yun M, Thangam R, You S-H, Zhang Y, et al. Imaging calreticulin for early detection of immunogenic cell death during anticancer treatment. J Nucl Med. 2021;62:956\u201360.","journal-title":"J Nucl Med"},{"key":"1767_CR21","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.3390\/cancers13112801","volume":"13","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Thangam R, You S-H, Sultonova RD, Venu A, Min JJ, et al. Engineering calreticulin-targeting monobodies to detect immunogenic cell death in cancer chemotherapy. Cancers. 2021;13:2801.","journal-title":"Cancers"},{"key":"1767_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1600-065X.2007.00567.x","volume":"220","author":"M Obeid","year":"2007","unstructured":"Obeid M, Tesniere A, Panaretakis T, Tufi R, Joza N, Van Endert P, et al. Ecto-calreticulin in immunogenic chemotherapy. Immunol Rev. 2007;220:22\u201334.","journal-title":"Immunol Rev"},{"key":"1767_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.pscia.2024.100048","volume":"2","author":"G Jia","year":"2024","unstructured":"Jia G, Jiang Y, Li X. Targeted drug conjugates in cancer therapy: Challenges and opportunities. Pharm Sci Adv. 2024;2:100048.","journal-title":"Pharm Sci Adv"},{"key":"1767_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/ird3.11","volume":"1","author":"R Luo","year":"2023","unstructured":"Luo R, Liu H, Cheng Z. High-throughput screening and biological display technology: Applications in molecular imaging. iRADIOLOGY. 2023;1:18\u201335.","journal-title":"iRADIOLOGY"},{"key":"1767_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115473","volume":"210","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Sultonova RD, You SH, Choi Y, Kim SY, Lee WS, et al. The anticancer effect of PASylated calreticulin-targeting L-ASNase in solid tumor bearing mice with immunogenic cell death-inducing chemotherapy. Biochem Pharmacol. 2023;210:115473.","journal-title":"Biochem Pharmacol."},{"key":"1767_CR26","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.7150\/thno.90376","volume":"14","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Akhil V, Seo HS, Park HR, Kim SH, You SH, et al. The combination of calreticulin-targeting L-ASNase and anti-PD-L1 antibody modulates the tumor immune microenvironment to synergistically enhance the antitumor efficacy of radiotherapy. Theranostics. 2024;14:1195.","journal-title":"Theranostics"},{"key":"1767_CR27","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.3390\/cancers14071782","volume":"14","author":"JM Oh","year":"2022","unstructured":"Oh JM, Rajendran RL, Gangadaran P, Hong CM, Jeong JH, Lee J, et al. Targeting GLI1 transcription factor for restoring iodine avidity with redifferentiation in radioactive-iodine refractory thyroid cancers. Cancers. 2022;14:1782.","journal-title":"Cancers"},{"key":"1767_CR28","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/1754-9485.13413","volume":"66","author":"D Czajkowski","year":"2022","unstructured":"Czajkowski D, Szmyd R, Gee HE. Impact of DNA damage response defects in cancer cells on response to immunotherapy and radiotherapy. J Med Imaging Radiat Oncol. 2022;66:546\u201359.","journal-title":"J Med Imaging Radiat Oncol"},{"key":"1767_CR29","doi-asserted-by":"publisher","first-page":"4736","DOI":"10.3390\/molecules27154736","volume":"27","author":"JA Nickoloff","year":"2022","unstructured":"Nickoloff JA. Targeting replication stress response pathways to enhance genotoxic chemo- and radiotherapy. Molecules. 2022;27:4736.","journal-title":"Molecules"},{"key":"1767_CR30","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.jtho.2017.04.014","volume":"12","author":"X Gong","year":"2017","unstructured":"Gong X, Li X, Jiang T, Xie H, Zhu Z, Zhou F, et al. Combined radiotherapy and anti\u2013PD-L1 antibody synergistically enhances antitumor effect in non\u2013small cell lung cancer. J Thorac Oncol. 2017;12:1085\u201397.","journal-title":"J Thorac Oncol"},{"key":"1767_CR31","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.1021\/acs.molpharmaceut.2c00281","volume":"19","author":"X Wen","year":"2022","unstructured":"Wen X, Zeng X, Cheng X, Zeng X, Liu J, Zhang Y, et al. PD-L1-Targeted radionuclide therapy combined with \u03b1PD-L1 antibody immunotherapy synergistically improves the antitumor effect. Mol Pharmacol. 2022;19:3612\u201322.","journal-title":"Mol Pharmacol."},{"key":"1767_CR32","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.nucmedbio.2010.11.005","volume":"38","author":"R Guo","year":"2011","unstructured":"Guo R, Tian L, Han B, Xu H, Zhang M, Li B. Feasibility of a novel positive feedback effect of 131I-promoted Bac-Egr1-hNIS expression in malignant glioma via baculovirus. Nucl Med Biol. 2011;38:599\u2013604.","journal-title":"Nucl Med Biol"},{"key":"1767_CR33","doi-asserted-by":"publisher","first-page":"e0116531","DOI":"10.1371\/journal.pone.0116531","volume":"10","author":"S Shi","year":"2015","unstructured":"Shi S, Zhang M, Guo R, Miao Y, Hu J, Xi Y, et al. In vivo molecular imaging and radionuclide (131I) therapy of human nasopharyngeal carcinoma cells transfected with a lentivirus expressing sodium iodide symporter. PLoS One. 2015;10:e0116531.","journal-title":"PLoS One"},{"key":"1767_CR34","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3892\/or.2015.4420","volume":"35","author":"S Shi","year":"2016","unstructured":"Shi S, Zhang M, Guo R, Zhang M, Hu J, Xi Y, et al. 131I therapy mediated by sodium\/iodide symporter combined with kringle 5 has a synergistic therapeutic effect on glioma. Oncol Rep. 2016;35:691\u20138.","journal-title":"Oncol Rep"},{"key":"1767_CR35","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1158\/1535-7163.MCT-21-0791","volume":"21","author":"T Ertveldt","year":"2022","unstructured":"Ertveldt T, De Beck L, De Ridder K, Locy H, de Mey W, Goyvaerts C, et al. Targeted radionuclide therapy with low and high-dose lutetium-177\u2013labeled single domain antibodies induces distinct immune signatures in a mouse melanoma model. Mol Cancer Ther. 2022;21:1136\u201348.","journal-title":"Mol Cancer Ther"},{"key":"1767_CR36","doi-asserted-by":"publisher","first-page":"6768","DOI":"10.7150\/thno.101922","volume":"14","author":"M Yang","year":"2024","unstructured":"Yang M, Wang L, Qin S, Dai X, Li J, An L, et al. Role of damaged mitochondrial transfer in alpha-particle generator 212Pb radiation-induced bystander effect. Theranostics. 2024;14:6768\u201382.","journal-title":"Theranostics"},{"key":"1767_CR37","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ird3.30","volume":"1","author":"J Zhang","year":"2023","unstructured":"Zhang J, Qin S, Yang M, Zhang X, Zhang S, Yu F. Alpha-emitters and targeted alpha therapy in cancer treatment. iRADIOLOGY. 2023;1:245\u201361.","journal-title":"iRADIOLOGY"},{"key":"1767_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.pscia.2023.100009","volume":"1","author":"S Fu","year":"2023","unstructured":"Fu S, Ma Q, Li J, Wang Y, Yang C, Gu P, et al. Blockage of HSP90 and IDO1 pathway by \u03b1-MSH modified nanoelicitor to dual-facilitate mild photothermal therapy. Pharm Sci Adv. 2023;1:100009.","journal-title":"Pharm Sci Adv"},{"key":"1767_CR39","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/pro6.1232","volume":"8","author":"K Wang","year":"2024","unstructured":"Wang K, Yuan S. Current status and prospect of particle therapy for esophageal cancer. Precis Radiat Oncol. 2024;8:92\u20138.","journal-title":"Precis Radiat Oncol"},{"key":"1767_CR40","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/S1470-2045(06)70795-1","volume":"7","author":"EC Halperin","year":"2006","unstructured":"Halperin EC. Particle therapy and treatment of cancer. Lancet Oncol. 2006;7:676\u201385.","journal-title":"Lancet Oncol"},{"key":"1767_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.pscia.2024.100037","volume":"2","author":"Y Chen","year":"2024","unstructured":"Chen Y, Tao M, Wu X, Tang Z, Zhu Y, Gong K, et al. Current status and research progress of oncolytic virus. Pharm Sci Adv. 2024;2:100037.","journal-title":"Pharm Sci Adv"},{"key":"1767_CR42","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","volume":"20","author":"SZ Shalhout","year":"2023","unstructured":"Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023;20:160\u201377.","journal-title":"Nat Rev Clin Oncol"},{"key":"1767_CR43","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41571-024-00908-9","volume":"21","author":"S-Y Kwon","year":"2024","unstructured":"Kwon SY, Thi-Thu Ngo H, Son J, Hong Y, Min JJ. Exploiting bacteria for cancer immunotherapy. Nat Rev Clin Oncol. 2024;21:569\u201389.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01767-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01767-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01767-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T02:05:00Z","timestamp":1781834700000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01767-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1767"],"URL":"https:\/\/doi.org\/10.1038\/s41401-026-01767-z","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}